The company has initiated and participated in a number of public welfare drug assistance projects, enabling more and more patients to benefit from the progress of life sciences and to buy and afford highquality biological drugs. To date, Innovent Biologics’ patient assistance program has benefited more than , ordinary patients, with the total value of drug donations reaching RMB . billion. Innovent Biologics hopes to work with everyone to improve the development level of China's biopharmaceutical industry to meet people's access to medicines and their pursuit of a better life and health.
For more information, please visit the company's website: nnoventbioom or the company's LinkedIn account : inkedinomcompanyinnoventbiologics .
Statement: . Innovent Biologics does not recommend the use of unapproved drugsindications.
. Ramucirumab injection Ciranze®, sepretinib capsules Reitu® and switzerland phone number list pitubutinib tablets Jepagliflozin® were developed by Eli Lilly and Company
The information contained in this press release may contain certain forwardlooking statements. These statements are inherently subject to considerable risks and uncertainties. When used in conjunction with the Company, the words "anticipate," "believe," "forecast," "expect," "intend" and other similar expressions are intended to identify forwardlooking statements. The Company undertakes no obligation to continually update these forwardlooking statements.